Which medication is primarily used to reduce treatment-related sexual adverse effects in BPH?

The most appropriate medication to reduce treatment-related sexual adverse effects in benign prostatic hyperplasia (BPH) is Tadalafil. This medication is a phosphodiesterase type 5 (PDE5) inhibitor, which is primarily used for erectile dysfunction. In addition to treating erectile dysfunction, Tadalafil has been found to improve sexual function in men undergoing treatment for BPH, particularly when combined with alpha-blockers, which can sometimes lead to sexual side effects.

In the context of BPH treatment, while other medications like Finasteride and Tamsulosin are commonly used, they may contribute to sexual adverse effects like decreased libido or erectile dysfunction. Therefore, Tadalafil serves a dual purpose: alleviating the symptoms of BPH while also addressing the sexual side effects that may arise from other BPH treatments. This capability makes Tadalafil a suitable option for patients who are concerned about preserving their sexual function during BPH therapy.